OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

News Market Reaction 1 Alert

+6.33% News Effect

$1.68 Close Price

+$14M Valuation Impact

$227M Market Cap

0.5x Rel. Volume

On the day this news was published, OABI gained 6.33%, reflecting a notable positive market reaction. The stock closed at $1.68 on that trading session. This price movement added approximately $14M to the company's valuation, bringing the market cap to $227M at that time.

Data tracked by StockTitan Argus on the day of publication.

09/02/2025 - 08:00 AM

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI) today announced that management will participate at the H.C. Wainwright 27^th Annual Global Investment Conference taking place September 8-10, 2025 at the Lotte New York Palace Hotel. Management will be available for one-on-one meetings on Tuesday, September 9^th with investors registered for the event.

Investors interested in scheduling a meeting with OmniAb management should contact their H.C. Wainwright representative, or email meetings@hcwco.com.

About OmniAb^®

OmniAb licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, is used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.

For more information, please visit www.omniab.com.